FORMULATION OF PACLITAXEL LOADED NANOSTRUCTURED LIPID CARRIERS TO STUDY THE EFFECT OF CONCENTRATION OF LIQUID LIPIDS ON DRUG RELEASE by Majumdar, Arti & Dubey, Nidhi
Majumdar et al                                                                                                     Journal of Drug Delivery & Therapeutics. 2017; 7(7):26-28                      
ISSN: 2250-1177                                                                                [26]                                                                             CODEN (USA): JDDTAO 
Available online on 25.12.2017 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-
commercial use, provided the original work is properly cited 
Open  Access                                                                                                                     Research Article 
FORMULATION OF PACLITAXEL LOADED NANOSTRUCTURED LIPID 
CARRIERS TO STUDY THE EFFECT OF CONCENTRATION OF LIQUID 
LIPIDS ON DRUG RELEASE 
Arti Majumdar
1
, Nidhi Dubey
2
 
1
Smriti College of Pharmaceutical Education, Indore, India 
2
School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore, India 
E-mail address: artijmajumdar10@gmail.com 
 
ABSTRACT 
In the present study, stearic acid (SA) nanostuctured lipid carriers (NLC) with different proportions of oleic acid (OA) were 
successfully prepared by solvent diffusion method in an aqueous system. OA was taken in the concentration of 10%, 20%, 30%, 
40% and 50%. Prepared NLCs were evaluated for various parameters like drug entrapment efficiency, drug loading and in vitro 
release. A biphasic drug release pattern was observed; initially a fast release was obtained followed by sustained release at a constant 
rate. The drug release from nanoparticles was found to be significantly influenced by OA content.  
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INTRODUCTION:  
The exponential development in the field of 
nanotechnology has revolutionized the research in the 
field of advanced drug delivery. Many times problems 
such as poor solubility, normal tissue toxicity, poor 
specificity, high incidence rate of pharmaceutical 
resistance and the rapid degradation, need of large-scale 
output procedures, a fast release of the pharmaceutical 
from its carrier, steadiness issues, the residues of the 
organic solvents utilized in the formulation method, the 
toxicity from the polymer and sometimes drug expulsion 
are encountered in the delivery of anticancer drugs 
through other colloidal delivery systems. These 
shortcomings are anticipated to be overcome through use 
of the nanostructured Lipid Carriers along with the 
advantage of high drug loading capacity and stability. 
Many nano delivery systems have been studied for the 
treatment of skin cancers, including liposome, 
polymersomes, carbon-based nanoparticles, inorganic 
nanoparticles, protein-based nanoparticles, 
nanostructured lipid carriers
1
, dendrimers
2 
and Self-nano 
emulsifying drug delivery
3, 4
. 
Lipid-based drug delivery systems have been proved 
as promising carriers for cytotoxic drugs because of 
their potential to increase the solubility and 
bioavailability of poorly water-soluble and/or 
lipophilic drugs
1
. The combination of nanoparticulate 
delivery system with lipids resulted in the 
development of a new class of NPs commonly known 
as solid lipid NPs (SLN). As SLN are composed of 
solid lipids only. Therefore, during formulation a part of 
the lipid crystallizes in a higher energy modification (α 
or β). Further on storage, these modifications can 
transform to more organized lower energy, β 
modification which further leads to drug expulsion. 
Apart from polymorphic transition, SLNs also show 
some disadvantages as drug carriers including an 
unpredictable gelation tendency, and low incorporation 
due to the crystalline structure of solid lipids. To 
overcome these limitations of the SLNs, second 
generation encapsulation systems have been developed 
by incorporating liquid carrier oil into the solid lipid 
matrix to form nanostructured lipid carriers (NLCs) thus 
NLCs were introduced. NLCs have shown to have 
improved active drug encapsulation and delivery 
properties compared to SLNs. The major advantage of 
nanostructured lipid carrier as drug delivery system is 
its ability to accommodate large quantities of drugs as 
a result of formation of a less ordered lipid matrix 
with many imperfections
5, 6
.  
MATERIALS AND METHODS:  
Materials:  
Stearic acid (LobaChemie, India) was used as solid lipid 
material of NLC. Oleic acid (LobaChemie, India) was 
Majumdar et al                                                                                                     Journal of Drug Delivery & Therapeutics. 2017; 7(7):26-28                      
ISSN: 2250-1177                                                                                [27]                                                                             CODEN (USA): JDDTAO 
used as liquid lipid material for NLC. Paclitaxel was 
kindly donated by Intas Pharmaceutical Ltd., 
Ahmedabad. The surfactant, sodium lauryl sulfate, was 
provided by Merck Specialities Pvt. Ltd., Mumbai. 
Ethanol, acetone and other chemicals were analytical 
reagent grade. 
Preparation of Paclitaxel loaded NLCs dispersion:  
PTX-loaded NLCs were prepared by solvent diffusion 
method in an aqueous system as reported earlier with 
slight modification
5
. Briefly,290 mg selected lipid (SA 
and OA) with varing content of OA ( 0%, 10%, 20%, 
30%, 40% and 50%) and 10mg drug were dissolved 
completely in a 16 ml mixture of acetone and ethanol 
(1:1, v/v) in water bath at 70 ◦C. This lipid solution was 
poured into 100 ml of an aqueous phase containing 
10mg of SLS under continuous mechanical agitation 
(Remi Instruments, Mumbai, India) with 3000 rpm at 
room temperature (25–28 ◦C) for 5 min. The pH value of 
the acidic aqueous phase was adjusted to 1.20 by 
addition of 0.1 M hydrochloric acid to form aggregation 
of nanoparticles. The aggregate of nanoparticle 
dispersion was then centrifuged 25,000 rpm for 20 min, 
to get the precipitate of nanostructuered carriers. The 
precipitate was collected for drug entrapment efficiency 
determination. 
Particle size measurement:  
The volume average diameter of drug-free or drug-
loaded nanoparticles in dispersion was determined with 
Particle Mastersizer 2000 (Malvern Instruments, UK) 
after diluted 20 times with distilled water. 
Drug entrapment efficiency determination 
The precipitate of drug-loaded nanoparticles were 
dispersed in 100 ml of 1 wt% sodium lauryl sulfate 
solution and shaken for 3 min to dissolve the free drugs. 
The resulting dispersions were centrifuged for 20 min at 
25,000 rpm. The drug content in the supernatant was 
analyzed by UV-VIS spectrophotometer (UV-1800 
Shimadzu Spectrophotometer) at 228nm. The 
entrapment efficacy and drug loading of nanoparticle 
was calculated using: 
EE = (Wα– Ws) / Wα X 100……………….................(i) 
DL = (Wα – Ws) / (Wα – Ws + Wl) X 100………….(ii) 
Where, EE is entrapment efficiency, DL is Drug loading, 
Wα stands for the weight of PTX added to the 
formulation and Ws is the analyzed weight of drug in 
supernatant and Wl is weight of lipid. 
In Vitro release assay 
The drug release profiles from nanoparticles were 
measured in vitro. 100mg of powdered nano structured 
lipid carriers were dispersed in 30 ml sodium lauryl 
sulfate solution (1 wt %) in 50 ml glass test-tube. The 
resulting samples were shaken for 3 min, and one 
milliliter of the dispersion was withdrawn from the 
system at definite time interval and filtrated with 100 nm 
filter. The filtrate was determined by UV-VIS 
spectrophotometer (UV-1800 Shimadzu 
Spectrophotometer) at 228nm as described above. 
RESULTS AND DISCUSSION: 
Preparation of stearic acid SLN (0%OA) and NLC 
by solvent diffusion method in an aqueous system 
The stearic acid SLN (0% OA) and NLC with 10, 20, 
30, 40 and 50wt% OA content, respectively, were 
prepared by solvent diffusion method in an aqueous 
system. 
Drug entrapment efficiency and Drug loading 
capacity 
The effects of OA on drug entrapment efficiency and 
loading capacity of formulations of all the batches were 
investigated. The curves of drug entrapment efficiency 
and loading capacity against OA content are given in 
Figure.1 and Figure.2. It is clear that the drug 
entrapment efficiency and drug loading capacity of 
nanoparticles were increased from 48.92 to 82.86% and 
from 1.65 to 2.78%, respectively, with increasing the 
percentage of OA from 0 to 50 wt%. 
 
Figure 1: Drug entrapment efficiency (EE) of various 
batches NLC against oleic acid (OA) content (n = 3). 
 
Figure 2: Drug loading (DL) of various batches NLC 
against oleic acid (OA) content (n = 3) 
In Vitro Drug release 
In Vitro release curves of six type drug-loaded 
nanoparticles are shown in Fig. 3. A biphasic drug 
release pattern was observed; initially a fast release was 
obtained followed by sustained release at a constant rate. 
The drug released was found to be slowest from stearic 
acid SLN ie.0% OA formulation. The release rate 
became faster when the OA was incorporated to 
nanoparticles and it increased with increasing the OA 
content. As shown in Table 1, the nanoparticles with less 
than 20 wt% OA content had almost similar mean size, 
but the release rate at the initial stage increased with the 
increasing OA content in nanoparticles. This means the 
OA content is a main factor affecting the drug release 
rate at the initial stage when the OA content was lower 
than 20 wt%. On the other hand, when the OA content 
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increased up to 50 wt%, the particle size significantly 
decreased, consequently, the specific surface area was 
increased. Therefore, the fastest release rate in initial 
stage, observed in the nanoparticles of 50 wt% OA 
content, was resulted by both of smaller size and higher 
OA content. However, later it was noticed that the 
release profiles of all the batches were almost parallel 
with each other. This result revealed that the OA almost 
did not affect the drug release rate of OA incorporated 
nanoparticles after initial stage. This may be due to 
nonhomogenous distribution of OA in nanoparticles. 
When solvent diffusion method at 70 ◦C was applied to 
prepare NLC, during cooling down process from the 
melted lipid droplet in dispersed medium to the 
formation of a nanostructured lipid carrier at room 
temperature, because of the different melting point 
between solid lipid and liquid lipid, the solid lipid 
(stearic acid) having higher melting point could 
crystallize first forming a liquid lipid free or little liquid 
lipid core, finally, most of the liquid lipid located at the 
outer shell of the nanoparticles which led to drug-
enriched shell related with drug burst release at the 
initial stage observed above. The OA-enriched outer 
layers possessed a soft and considerable higher solubility 
for lipophilic drugs character, in which the drug was 
easily loaded to higher amount and could be easily 
released as well by the drug diffusion or the matrix 
erosion manners. Therefore, the OA incorporated 
nanoparticles showed the burst release at the initial stage 
and sustained release later. 
 
Table1: Particle size of various batches of Drug free and Drug loaded NLCs 
OA Wt% Particle size (nm) 
Drug –free nanoparticles Drug loaded nanoparticles 
0 412±2.8 476±6.3 
10 409±6.2 471±1.8 
20 399±7.9 458±2.6 
30 209±1.2 265±3.9 
40 189±3.8 228±1.3 
50 174±9.1 212±5.2 
 
 
Figure 3: Cumulative in vitro drug release from various batches having OA in different proportions 
CONCLUSION: 
A solvent diffusion method in aqueous system was 
employed to prepare the OA–SA NLC with improved 
drug incorporation and release properties. The drug 
release characteristics from the NLC exhibited a 
biphasic pattern with burst release at the initial stage and 
followed by sustained release at a constant rate. The 
drug release rate at the initial stage and the drug 
entrapment efficiency of the NLC were increased with 
increasing the content of liquid lipid (OA). These results 
proved that the NLC prepared in the present study can 
be successfully used as a carrier for therapeutic drug 
delivery.
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